Latest News

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.

Healthcare.gov takes on Heartbleed

Officials are asking users to change passwords, as an added precaution.

Sovaldi Rx are being filled, despite payer angst

Sovaldi Rx are being filled, despite payer angst

Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.

Sarepta plans for 2015 drug review

Sarepta plans for 2015 drug review

The company said it plans to file its rare-disease drug with the FDA later this year, for a 2015 review.

Court won't stall generic Copaxone

Court won't stall generic Copaxone

The Supreme Court denied Teva's request to keep branded Copaxone off the market while the appeals process shakes out.

Email Newsletters